Stock listing
Stockholm:NXTCL NextCell Pharma AB Aktie
Home listing (Stockholm) of NextCell Pharma AB
Follow NextCell Pharma AB into a list and get an email when it puts out news.
Share price · OMXSTO:NXTCL
0.218 SEK -0.011 (-4.6%)
Close on Nov 20, 2026
- Day range
- 0.199 – 0.236 SEKNov 20, 2026
- Volume
- 1.44M sharesNov 20, 2026
- Market cap
- 27.49M SEKAt the close on Nov 20, 2026 · price × 126.4M shares outstanding
- 52-week range
- 0.199 – 1.784 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 409,237 SEKMedian day 342,455 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:NXTCL · Home | 0.218 SEK | -0.011 (-4.6%) | 1,444,277 | 0.236 | 0.236 | 0.199 | 0.228 | Close on Nov 20, 2026 |
| Frankfurt:65G | €0.0064 EUR | +0.0010 (+18.5%) | — | €0.0064 | €0.0064 | €0.0064 | €0.0054 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:NXTCL · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 0.218 | -0.011 | -4.6% | 0.236 | 0.236 | 0.199 | 1,444,277 | |
| 0.228 | -0.016 | -6.7% | 0.230 | 0.247 | 0.221 | 88,823 | |
| 0.245 | +0.018 | +7.9% | 0.240 | 0.249 | 0.225 | 428,962 | |
| 0.227 | -0.013 | -5.6% | 0.260 | 0.260 | 0.222 | 343,437 | |
| 0.240 | +0.002 | +0.6% | 0.245 | 0.263 | 0.239 | 776,936 | |
| 0.239 | -0.010 | -4.0% | 0.241 | 0.262 | 0.239 | 179,616 | |
| 0.249 | -0.033 | -11.7% | 0.255 | 0.263 | 0.241 | 190,060 | |
| 0.282 | +0.013 | +5.0% | 0.270 | 0.294 | 0.263 | 654,236 | |
| 0.268 | -0.022 | -7.6% | 0.291 | 0.291 | 0.260 | 341,473 | |
| 0.290 | +0.004 | +1.2% | 0.285 | 0.294 | 0.282 | 261,505 | |
| 0.287 | +0.033 | +13.0% | 0.231 | 0.300 | 0.231 | 549,538 | |
| 0.254 | +0.023 | +10.2% | 0.232 | 0.286 | 0.232 | 1,318,377 | |
| 0.230 | -0.035 | -13.2% | 0.260 | 0.264 | 0.200 | 1,561,388 | |
| 0.265 | -0.046 | -14.8% | 0.318 | 0.325 | 0.265 | 1,887,788 | |
| 0.311 | +0.010 | +3.2% | 0.325 | 0.422 | 0.261 | 2,979,360 | |
| 0.302 | -0.128 | -29.7% | 0.415 | 0.430 | 0.291 | 6,153,623 | |
| 0.429 | -0.571 | -57.1% | 0.376 | 0.530 | 0.376 | 8,444,404 | |
| 1.000 | +0.005 | +0.5% | 0.933 | 1.000 | 0.928 | 263,620 | |
| 0.995 | +0.035 | +3.6% | 0.960 | 0.995 | 0.937 | 213,052 | |
| 0.960 | -0.040 | -4.0% | 1.004 | 1.004 | 0.951 | 87,051 | |
| 1.000 | -0.004 | -0.4% | 0.993 | 1.006 | 0.952 | 107,449 | |
| 1.004 | +0.048 | +5.0% | 0.985 | 1.006 | 0.957 | 263,881 | |
| 0.956 | -0.062 | -6.1% | 0.992 | 1.000 | 0.936 | 365,113 | |
| 1.018 | -0.026 | -2.5% | 0.975 | 1.034 | 0.975 | 71,212 | |
| 1.044 | +0.062 | +6.3% | 0.981 | 1.044 | 0.955 | 506,627 | |
| 0.982 | +0.019 | +2.0% | 0.964 | 0.997 | 0.939 | 467,298 | |
| 0.963 | -0.049 | -4.8% | 1.012 | 1.012 | 0.952 | 382,850 | |
| 1.012 | +0.012 | +1.2% | 1.012 | 1.024 | 0.985 | 94,815 | |
| 1.000 | -0.020 | -2.0% | 1.000 | 1.006 | 0.972 | 239,584 | |
| 1.020 | -0.070 | -6.4% | 1.052 | 1.052 | 1.020 | 263,436 | |
| 1.090 | +0.050 | +4.8% | 1.042 | 1.104 | 1.038 | 271,498 | |
| 1.040 | 0.000 | 0.0% | 1.040 | 1.052 | 1.000 | 380,410 | |
| 1.040 | -0.058 | -5.3% | 1.054 | 1.060 | 0.980 | 1,050,508 | |
| 1.098 | -0.020 | -1.8% | 1.118 | 1.118 | 1.048 | 100,845 | |
| 1.118 | +0.018 | +1.6% | 1.098 | 1.130 | 1.046 | 153,546 | |
| 1.100 | +0.076 | +7.4% | 1.020 | 1.122 | 0.969 | 334,288 | |
| 1.024 | +0.006 | +0.6% | 1.000 | 1.042 | 0.968 | 455,740 | |
| 1.018 | +0.006 | +0.6% | 1.008 | 1.054 | 0.996 | 557,732 | |
| 1.012 | -0.044 | -4.2% | 1.056 | 1.056 | 1.000 | 345,928 | |
| 1.056 | +0.010 | +1.0% | 1.044 | 1.056 | 1.036 | 116,523 | |
| 1.046 | -0.032 | -3.0% | 1.080 | 1.080 | 1.030 | 230,669 | |
| 1.078 | +0.008 | +0.7% | 1.080 | 1.080 | 1.050 | 316,254 | |
| 1.070 | 0.000 | 0.0% | 1.068 | 1.070 | 1.038 | 207,704 | |
| 1.070 | -0.030 | -2.7% | 1.096 | 1.098 | 1.050 | 147,371 | |
| 1.100 | +0.054 | +5.2% | 1.112 | 1.112 | 1.050 | 66,684 | |
| 1.046 | -0.012 | -1.1% | 1.058 | 1.068 | 1.016 | 273,950 | |
| 1.058 | -0.028 | -2.6% | 1.088 | 1.098 | 1.040 | 491,491 | |
| 1.086 | -0.064 | -5.6% | 1.148 | 1.148 | 1.070 | 106,761 | |
| 1.150 | +0.020 | +1.8% | 1.130 | 1.150 | 1.090 | 312,619 | |
| 1.130 | +0.078 | +7.4% | 1.052 | 1.130 | 1.010 | 960,489 | |
| 1.052 | -0.018 | -1.7% | 1.072 | 1.100 | 1.048 | 357,389 | |
| 1.070 | +0.030 | +2.9% | 1.032 | 1.080 | 0.997 | 957,910 | |
| 1.040 | -0.060 | -5.5% | 1.100 | 1.100 | 1.030 | 867,751 | |
| 1.100 | +0.012 | +1.1% | 1.138 | 1.138 | 1.000 | 526,630 | |
| 1.088 | +0.008 | +0.7% | 1.098 | 1.150 | 1.060 | 58,461 | |
| 1.080 | +0.030 | +2.9% | 1.092 | 1.098 | 1.046 | 293,251 | |
| 1.050 | -0.050 | -4.5% | 1.080 | 1.150 | 1.050 | 360,342 | |
| 1.100 | +0.052 | +5.0% | 1.056 | 1.100 | 1.042 | 173,729 | |
| 1.048 | -0.014 | -1.3% | 1.058 | 1.100 | 1.014 | 273,534 | |
| 1.062 | -0.054 | -4.8% | 1.188 | 1.188 | 1.056 | 312,618 | |
| 1.116 | +0.014 | +1.3% | 1.124 | 1.182 | 1.060 | 393,543 | |
| 1.102 | -0.078 | -6.6% | 1.176 | 1.200 | 1.100 | 445,537 | |
| 1.180 | +0.080 | +7.3% | 1.100 | 1.238 | 0.997 | 571,465 | |
| 1.100 | -0.190 | -14.7% | 1.300 | 1.300 | 1.074 | 523,993 |
- Ticker
- Stockholm:NXTCL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stockholm
- Currency
- SEK
What changed lately
Latest news release · Jan 21, 2026
NextCell decides to propose a directed share issue of SEK 15 million
Latest news
NextCell decides to propose a directed share issue of SEK 15 million
Jan 21, 2026
Closed 1.45 (-12.1%) on Jan 21, 2026
NextCell Pharma AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in the last 12 months · 3 in all · newest Jan 21, 2026 · oldest 2025
Where NextCell Pharma AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:NXTCL · Home listing · This page | Stockholm | Sweden | SEK |
| Frankfurt:65G | Frankfurt | Germany | EUR |
Valuation
EV/sales 0.6× against a median of 32.8×: the lowest of 5 Biotechnology companies shown. Statements: 4 quarters to May 31, 2026 · price Nov 20, 2026
- Enterprise value
- 6.40M SEK
- P/E
- Loss
- EV/sales
- 0.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.6×
- Gross margin
- −447.6%
- Operating margin
- −447.6%
- Net margin
- −440.8%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| NextCell Pharma AB · OMXSTO:NXTCL | US$2.69M | US$626,140 | n/a | 0.6× | n/a | 0.6× | −440.8% | 0.0× | n/a |
| Gelteq Limited · NASDAQ:GELS | US$2.89M | US$6.27M | n/a | 57.2× | n/a | 0.3× | n/a | 0.4× | 0.83 |
| Curis, Inc. · NASDAQ:CRIS | US$2.85M | −US$1.42M | n/a | n/a | n/a | 1.1× | n/a | 0.3× | 1.85 |
| Fluicell AB · OMXSTO:FLUI | US$2.83M | US$3.03M | 10.4× | 1.6× | 10.7× | 1.8× | 14.1% | 0.1× | n/a |
| Alligator Bioscience AB · OMXSTO:ATORX | US$2.79M | US$1.47M | n/a | 53.3× | n/a | 1.2× | n/a | 1.2× | n/a |
| Traws Pharma, Inc. · NASDAQ:TRAW | US$2.69M | US$351,448 | n/a | n/a | n/a | n/a | n/a | n/a | 2.07 |
| Bioxytran, Inc. · OTC:BIXT | US$2.66M | US$2.59M | n/a | n/a | n/a | n/a | n/a | n/a | -1.20 |
| BioAtla, Inc. · NASDAQ:BCAB | US$2.58M | US$2.01M | n/a | n/a | n/a | n/a | n/a | n/a | -0.34 |
| Invion Ltd. · ASX:IVX | US$2.49M | US$3.12M | n/a | 12.2× | n/a | 0.7× | n/a | 0.3× | n/a |
| GRI Bio, Inc. · NASDAQ:GRI | US$2.45M | −US$6.99M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.89 |
| NeuroSense Therapeutics Ltd. · NASDAQ:NRSN | US$2.43M | US$2.20M | n/a | n/a | n/a | n/a | n/a | n/a | 1.41 |
| Median of the others | US$2.68M | US$2.10M | 10.4× | 32.8× | 10.7× | 0.9× | 14.1% | 0.3× | 0.89 |
Forecasts
Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 0.80 SEK · Analysts' mean
- Revenue, year to Dec 2026
- 12M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Mathias Svahn | CEO |
| Eric Gustafsson | CFO |
Board
| Director | Role |
|---|---|
| Camilla Myhre Sandberg | Board member |
| Edvard Smith | Board Member |
| Eva Sjökvist Saers | Board Member |
| Hans-Peter Ekre | Chariman of the Board |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Jun 30, 2026 | −8.9% |
| Q2 2026 | Mar 31, 2026 | −4.8% |
| Q1 2026 | Dec 31, 2025 | −4.0% |
| Q4 2025 | Oct 30, 2025 · After close | +0.8% |
| Q3 2025 | Jul 24, 2025 | +10.3% |
| Q2 2025 | Apr 25, 2025 | −4.0% |
| Q1 2025 | Jan 29, 2025 | −3.4% |
| Q1 2022 | Jan 28, 2022 · Before open | +3.6% |
| Q4 2021 | Oct 29, 2021 | −6.4% |
| Quarter to May 31, 2021 | Jul 30, 2021 | +5.5% |
All 12 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Feb 28, 2021 | Apr 29, 2021 | −7.5% |
| Quarter to Nov 30, 2020 | Jan 29, 2021 | −2.5% |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of shares Announced: SEK 15M · SEK 1 a share · Delphi KB Dealers: Delphi KB Buyers: Rustan Panday, through Jehangir AB; Anders Eriksson; Mats Gustafsson; Michaëla Berglund; India von Platen Use of proceeds: Continued development of drug candidate ProTrans and strengthening working capital | Jan 21, 2026 | US$1.65M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.9M | 10.7M | 10.1M | 5.59M | 3.91M | 3.56M | 1.81M | 655.4K | 517.2K | 809.0K |
| Cost of revenue | 46.8M | 15.2M | 11.0M | 27.8M | 18.4M | 13.9M | 15.8M | 8.83M | 3.19M | 5.87M |
| Gross profit | -35.9M | -4.56M | -884.8K | -22.3M | -14.5M | -10.4M | -14.0M | -8.17M | -2.67M | -5.06M |
| Selling, general and administrative | 8.50M | 7.17M | 10.2M | 4.85M | 6.53M | 5.13M | ||||
| Operating income | -35.9M | -43.2M | -41.0M | -35.0M | -24.8M | -17.7M | -21.5M | -14.0M | -13.3M | -11.4M |
| Depreciation and amortization | 2.52M | 974.7K | 447.9K | 457.3K | 437.0K | 397.1K | 348.3K | 298.7K | 298.7K | 298.7K |
| EBITDA | -33.4M | -42.2M | -40.6M | -34.6M | -24.4M | -17.3M | -21.1M | -13.7M | -13.0M | -11.1M |
| Interest expense | 2.60K | 1.36K | 2.81K | 13.5K | 7.57K | 8.84K | 7.79K | 16.2K | 1.90K | 1.27K |
| Income before tax | -35.1M | -42.0M | -39.8M | -34.6M | -24.6M | -17.7M | -21.5M | -14.0M | -13.2M | -11.4M |
| Income tax | 1.79M | 1.19M | -469.6K | 7.57K | 8.84K | 7.79K | 30.6K | 17.5K | 14.0K | |
| Net income | -35.1M | -42.0M | -39.8M | -34.1M | -24.6M | -17.7M | -21.5M | -14.0M | -13.2M | -11.4M |
| Earnings per share, basic | -0.46 | -0.57 | -0.58 | -0.50 | -0.81 | -0.80 | -1.37 | -0.82 | -1.67 | -2.18 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 38.7M | 46.8M | 50.0M | 97.1M | 139.2M | 22.0M | 20.1M | 3.12M | 16.6M | 5.85M |
| Short-term investments | -1.08M | -1.13M | -1.13M | -1.13M | ||||||
| Receivables | 15.1M | 13.3M | 16.5M | 8.87M | 7.31M | 4.07M | 3.07M | 1.93M | 1.26M | 301.8K |
| Inventory | 545.2K | 545.2K | 790.7K | 767.0K | 1 | 1 | -2.71M | -1.93M | 1 | -592.2K |
| Current assets | 54.4M | 60.6M | 67.3M | 106.8M | 146.5M | 26.0M | 23.2M | 5.04M | 17.9M | 6.44M |
| Property, plant and equipment | 9.90M | 2.90M | 2.61M | 2.48M | 2.43M | 2.73M | 3.02M | |||
| Total assets | 76.7M | 81.3M | 88.8M | 124.7M | 155.6M | 29.8M | 26.7M | 8.51M | 21.6M | 9.47M |
| Accounts payable | 2.69M | 6.16M | 891.6K | 1.92M | 1.28M | 477.6K | 1.42M | 651.8K | 878.1K | 552.7K |
| Current liabilities | 5.43M | 9.87M | 10.1M | 6.93M | 3.96M | 2.17M | 2.82M | 2.71M | 1.86M | 2.00M |
| Total liabilities | 10.3M | 13.7M | 13.1M | 9.12M | 5.53M | 3.56M | 3.76M | 3.47M | 2.55M | 2.70M |
| Shareholders' equity | 66.4M | 67.6M | 75.7M | 115.5M | 150.1M | 26.2M | 23.0M | 5.04M | 19.1M | 6.76M |
| Shares outstanding | 76.4M | 73.1M | 68.8M | 68.8M | 30.4M | 22.2M | 15.7M | 17.0M | 7.93M | 5.23M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -38.9M | -37.8M | -43.8M | -33.3M | -25.6M | -19.0M | -22.1M | -13.5M | -14.8M | -11.1M |
| Capital spending | -4.18M | -82.9K | -4.10M | -7.59M | -725.9K | -787.1K | -396.5K | -396.5K | -396.5K | -142.1K |
| Free cash flow | -43.0M | -37.9M | -47.9M | -40.9M | -26.3M | -19.7M | -22.5M | -13.5M | -14.8M | -11.3M |
| Cash from investing | -4.24M | -83.5K | -4.10M | -9.37M | -5.84M | -590.0K | -401.5K | -401.5K | -401.5K | -142.1K |
| Cash from financing | 35.0M | 34.6M | 835.7K | 608.2K | 148.6M | 21.4M | 39.5M | 64.7K | 25.6M | 8.39M |
| Change in cash | -8.07M | -3.23M | -47.1M | -42.1M | 117.2M | 1.83M | 17.0M | -13.5M | 10.8M | -2.85M |
Cap table
Built by 6ix from NextCell Pharma AB’s releases · as of Jan 21, 2026
- Common shares
- 126,392,959
- Fully diluted
- 126,392,959
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 126,392,959 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 126,392,959 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Camilla Myhre Sandberg | Board member · Since at least Nov 5, 2026 |
| Edvard Smith | Board Member · Since at least Nov 5, 2026 |
| Eric Gustafsson | CFO · Since at least Nov 20, 2025 |
| Eva Sjökvist Saers | Board Member · Since at least Nov 5, 2026 |
| Hans-Peter Ekre | Chariman of the Board · Since at least Nov 5, 2026 |
| Mathias Svahn | CEO · Since at least Nov 20, 2025 |
Log in to ask 6ix AI your own questions about NextCell Pharma AB.